Syndax Pharma: Continuing Execution In AML
Summarize this article with:
Brendan O'Boyle2.1K FollowersFollow5ShareSavePlay(13min)CommentsSummarySyndax Pharmaceuticals is now a commercial-stage biopharma with two FDA-approved drugs: Revuforj and Niktimvo.Syndax's Revuforj leads in efficacy for AML, with rapid market penetration and a first-mover advantage in front-line Phase 3 trials.Despite cardiac risk concerns, lower-dose combination data suggest manageable safety, supporting Syndax's strong buy rating.Analysts project Syndax's sales to more than double by 2026, with profitability expected by 2027 and substantial long-term EPS growth.Md Ariful Islam/iStock via Getty Images Syndax Pharmaceuticals (NASDAQ:SNDX) has transitioned to a commercial-stage biopharma company with two FDA-approved drugs: Revuforj and Niktimvo. Revuforj is a first-in-class menin inhibitor approved for the treatment of relapsed or refractory (R/R) acuteThis article was written byBrendan O'Boyle2.1K FollowersFollowBrendan, a Pennsylvanian by birth:-Completed a Ph.D. at Stanford University in the field of organic synthesis (2009). -Worked for a major pharmaceutical company (Merck, 2009-2013).-Worked in biotech including start-ups (Theravance/Aspira) prior to securing employment at Caltech.-First employee and co-founder of 1200 Pharma as it spun out of Caltech garnering major investment (into the 8 figures).-Remains an avid investor, focused on market trends and especially biotechnology stocks.Analyst’s Disclosure:I/we have a beneficial long position in the shares of SNDX either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Disclaimer: All investment opportunities carry inherent risk, including potential loss of principle. Carefully consider your investment objectives, level of experience and risk appetite before making any investment. The above discussion is a framework for investors (both long and short), to understand the factors that will move the underlying security’s price. It is not a prediction and should not be considered investment advice. SNDX is a biotech stock and inherently a HIGH RISK investment. The author is long SNDX and KURA.Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.